Menten AI

Menten AI is a biotechnology company based in San Francisco, California, with additional operations in Toronto, Canada.

Founded in 2018 by Hans Melo, Tamas Gorbe, and Vikram Mulligan, the company focuses on developing cyclic peptide therapeutics and protein drugs using generative AI and quantum computing. Their proprietary platform, MAUD 1.0, enables the rapid design of macrocycles with drug-like properties, leveraging advanced technologies to address challenging drug targets. Menten AI primarily operates in the B2B space, offering services for drug discovery and enzyme engineering. Their core offerings include rational peptide design, enzyme optimization, and preclinical discovery acceleration. The company collaborates with pharmaceutical and biotech industries, including a notable partnership with Bristol Myers Squibb for cyclic peptide optimization. Menten AI is supported by prominent investors such as Y Combinator and Khosla Ventures, having raised approximately $4.36 million in funding.